TY - JOUR
T1 - Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children with sickle hemoglobinopathy or malignancies, and after systemic Haemophilus influenzae type b infection
AU - Kaplan, Sheldon
AU - Duckett, Teresa
AU - Mahoney, Donald H.
AU - Kennedy, Laura L.
AU - Dukes, Cindy M.
AU - Schaffer, Don M.
AU - Mason, Edward
PY - 1992/1/1
Y1 - 1992/1/1
N2 - To determine the immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in specific populations at risk, we administered vaccine to children with sickle cell anemia (n=19; mean age, 18.3 months, malignancies (n=18; mean age, 43.1 months), or a recent history of systemic H. influenzae type b infection (n=17; mean age, 11.9 months). After one dose of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine the geometric mean titers for polyribosylribitol phosphate antibody were 4.8 μg/ml (14/19 >1 μg/ml), 1.4 μg/ml (9/18 >1 μg/ml), and 5.6 μg/ml (15/17 >1 μg/ml) in these three groups, respectively. Children with sickle cell anemia or a recent history of systemic H. influenzae type b infection had polyribosylribitol phosphate antibody levels comparable to those of normal children of similar age after one or two doses of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine. We conclude that this vaccine is immunogenic in children with underlying conditions associated with an increased risk of H. influenzae type b infection.
AB - To determine the immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in specific populations at risk, we administered vaccine to children with sickle cell anemia (n=19; mean age, 18.3 months, malignancies (n=18; mean age, 43.1 months), or a recent history of systemic H. influenzae type b infection (n=17; mean age, 11.9 months). After one dose of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine the geometric mean titers for polyribosylribitol phosphate antibody were 4.8 μg/ml (14/19 >1 μg/ml), 1.4 μg/ml (9/18 >1 μg/ml), and 5.6 μg/ml (15/17 >1 μg/ml) in these three groups, respectively. Children with sickle cell anemia or a recent history of systemic H. influenzae type b infection had polyribosylribitol phosphate antibody levels comparable to those of normal children of similar age after one or two doses of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine. We conclude that this vaccine is immunogenic in children with underlying conditions associated with an increased risk of H. influenzae type b infection.
UR - http://www.scopus.com/inward/record.url?scp=0026594985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026594985&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(05)80898-4
DO - 10.1016/S0022-3476(05)80898-4
M3 - Article
C2 - 1538281
AN - SCOPUS:0026594985
SN - 0022-3476
VL - 120
SP - 367
EP - 370
JO - The Journal of Pediatrics
JF - The Journal of Pediatrics
IS - 3
ER -